Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
furaprevir + yimitasvir
- Development stage
- Unknown
- Lead developer
- TaiGen Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Furaprevir (TG-2349) and yimitasvir (DAG-181) are direct-acting antiviral agents developed as an all-oral combination therapy for the treatment of chronic hepatitis C virus (HCV) infection. Furaprevir is a small molecule NS3/NS4A protease inhibitor that blocks viral replication by inhibiting the HCV serine protease required for polyprotein processing. Yimitasvir is a small molecule NS5A inhibitor that interferes with viral RNA replication and assembly. The combination has been evaluated in multiple clinical trials, including Phase III studies in HCV genotype 1 infected patients, both with and without cirrhosis. The regimen may also be used with ribavirin in some protocols[1][2][3][4][5][6][7][8]. Developed through a joint venture between TaiGen Biotechnology and YiChang HEC ChangJiang Pharmaceutical (HEC), this fixed-dose cocktail targets improved sustained virologic response rates for hepatitis C.
- Other names
- TG-2349 + DAG181
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on furaprevir + yimitasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on furaprevir + yimitasvir.